Arlocabtagene autoleucel:靶向GPRC5D的CAR-T细胞疗法用于重度经治复发/难治多发性骨髓瘤
这项1期剂量递增/扩展研究纳入84例既往≥3线治疗(含免疫调节剂、蛋白酶体抑制剂和抗CD38抗体)的复发/难治多发性骨髓瘤患者,中位既往5线,49%曾接受BCMA靶向治疗。单次静脉输注arlo-cel(25–450×10^6 CAR-T细胞)后,未达到最大耐受剂量,细胞因子释放综合征发生率82%(多为1/2级),总缓解率87%(完全缓解率53%),中位无进展生存期18.3个月(95%CI 11.8–21.9),1年总生存率90%。
要点
- Arlo-cel在重度经治RRMM中总缓解率87%,完全缓解率53%,中位PFS 18.3个月。
- 细胞因子释放综合征发生率82%,多为1/2级,最高剂量组发生1例CRS相关死亡。
- 靶向/脱靶皮肤、指甲和口腔不良事件多为1/2级且短暂,多数无需干预自行缓解。
核心结论
- Arlo-cel在重度经治复发/难治多发性骨髓瘤中显示出可控的安全性和深度、持久的缓解,PFS和OS结果支持进一步临床研究。
研究设计与样本
- 1期剂量递增/扩展研究,纳入84例既往≥3线治疗(含免疫调节剂、蛋白酶体抑制剂和抗CD38抗体)的成人复发/难治多发性骨髓瘤患者。
- Arlo-cel单次静脉输注,剂量范围25–450×10^6 CAR-T细胞;主要终点为安全性和最大耐受剂量,次要终点包括总缓解率、无进展生存期和总生存期。
主要发现
- 患者中位既往治疗线数5线,49%曾接受BCMA靶向治疗。
- 细胞因子释放综合征发生率82%,免疫效应细胞相关神经毒性综合征10%,其他特定神经毒性12%;多数为1/2级,频率呈剂量依赖性。
- 最高剂量组发生1例细胞因子释放综合征相关死亡。
- 靶向/脱靶皮肤不良事件30%、指甲19%、口腔32%,均为短暂1/2级,多数无需干预自行缓解。
- 中位随访16.1个月,总缓解率87%(完全缓解率53%),中位缓解持续时间18.0个月,中位无进展生存期18.3个月(95%CI 11.8–21.9;n=79),1年总生存率90%(N=84)。
关键数值与推荐
- 未达到最大耐受剂量。
- 总缓解率87%,完全缓解率53%,中位缓解持续时间18.0个月,中位无进展生存期18.3个月(95%CI 11.8–21.9;n=79),1年总生存率90%(N=84)。
临床怎么用
- Arlo-cel可用于重度经治复发/难治多发性骨髓瘤(含BCMA靶向治疗后)患者,需监测细胞因子释放综合征和神经毒性,尤其在高剂量水平。
局限性
- 为1期单臂研究,样本量有限(N=84),随访时间中位16.1个月,长期疗效和安全性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel; BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). This phase 1, dose-escalation/expansion study enrolled adult patients with RRMM and ≥3 previous antimyeloma treatment regimens, including an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody. Patients (N = 84) had a median of 5 prior regimens, and 49% had previously received B-cell maturation antigen-targeted therapy. Arlo-cel was administered as a single IV infusion of 25 to 450 × 106 CAR T cells. Primary end points were safety and maximum tolerated dose (MTD); secondary end points included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Data cutoff was 23 August 2024. Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell-associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1/2 and frequency appeared dose-dependent. One death occurred from CRS at the highest dose level. On-target/off-tumor skin (30%), nail (19%), and oral (32%) adverse events were transient and grade 1/2; most resolved without intervention. MTD was not reached. With a median follow-up of 16.1 months, ORR was 87% (complete response rate, 53%), median duration of response was 18.0 months, median PFS was 18.3 months (95% confidence interval, 11.8-21.9; n = 79), and 1-year OS rate was 90% (N = 84). Arlo-cel showed a manageable safety profile and deep, durable responses, with promising PFS and OS in heavily pretreated RRMM, supportive of future clinical research. This trial was registered at www.clinicaltrials.gov as NCT04674813.
引用
- Bal S, Htut M, Nadeem O, et al. Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma. Blood. 2026. PMID: 42233419. doi:10.1182/blood.2025030750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。